New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - diphtheria toxoid, adsorbed 15 lf u; pertactin 3ug (adsorbed); pertussis filamentous haemagglutinin 20ug (adsorbed); pertussis fimbriae 2+3 5ug (adsorbed); pertussis toxoid, adsorbed 20ug; polio virus type 1 40 dagu (inactivated); polio virus type 2 8 dagu (inactivated); polio virus type 3 32 dagu (inactivated); tetanus toxoid, adsorbed 5 lf u; haemophilus influenzae type b polysaccharide 10ug (conjugated to tetanus protein (18-30µg)) - combination - active: diphtheria toxoid, adsorbed 15 lf u pertactin 3ug (adsorbed) pertussis filamentous haemagglutinin 20ug (adsorbed) pertussis fimbriae 2+3 5ug (adsorbed) pertussis toxoid, adsorbed 20ug polio virus type 1 40 dagu (inactivated) polio virus type 2 8 dagu (inactivated) polio virus type 3 32 dagu (inactivated) tetanus toxoid, adsorbed 5 lf u excipient: aluminium phosphate bovine serum albumin formaldehyde glutaral neomycin phenoxyethanol polymyxin b polysorbate 80 water for injection active: haemophilus influenzae type b polysaccharide 10ug (conjugated to tetanus protein (18-30µg)) excipient: sucrose trometamol - poliacel® is indicated for primary immunisation of children from the age of 2 months to 12 months against diphtheria, tetanus, whooping cough, poliomyelitis and invasive haemophilus influenzae type b disease. poliacel® is also indicated for the fourth dose for children from 15 to 20 months who have been immunised previously with up to three doses of diphtheria, tetanus, pertussis, polio and haemophilus influenzae type b disease vaccines.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

wyeth (nz) ltd - diphtheria toxoid, adsorbed 25 lf u/ml; haemophilus influenzae type b oligosaccharide vaccine-crm 197 conjugate 50 µg/ml; haemophilus influenzae type b vaccine 20 µg/ml; pertussis vaccine, adsorbed 32 iou; tetanus toxoid, adsorbed 10 lf u/ml - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 25 lf u/ml haemophilus influenzae type b oligosaccharide vaccine-crm 197 conjugate 50 µg/ml haemophilus influenzae type b vaccine 20 µg/ml pertussis vaccine, adsorbed 32 iou tetanus toxoid, adsorbed 10 lf u/ml excipient: aluminium sodium chloride thiomersal water for injection

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - diphtheria toxoid, adsorbed 25 lf u; pertussis vaccine 4 [iu]; tetanus toxoid, adsorbed 5 lf u - solution for injection - 25lf/5lf/4iu - active: diphtheria toxoid, adsorbed 25 lf u pertussis vaccine 4 [iu] tetanus toxoid, adsorbed 5 lf u

Iżrael - Ingliż - Ministry of Health

bayer israel ltd - levonorgestrel - intrauterine device - levonorgestrel 52 mg - levonorgestrel and estrogen - levonorgestrel and estrogen - contraception and idiopathic menorrhagia. protection from endometrial hyperplasia during estrogen replacement therapy.

Iżrael - Ingliż - Ministry of Health

bayer israel ltd - drospirenone; estradiol as hemihydrate - film coated tablets - drospirenone 2 mg; estradiol as hemihydrate 1 mg - estradiol - estradiol - angeliq is indicated for hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women more than 1 year post menopause. prevention of postmenopausal osteoporosis in women with an increased risk of future osteoporosis fractures.

Iżrael - Ingliż - Ministry of Health

merck sharp & dohme israel ltd - finasteride - tablets - finasteride 5 mg - finasteride - finasteride - for the treatment and control of benign prostatic hyperplasia (bph) and for the prevention of urologic events to: reduce the risk of acute urinary retention. reduce the risk of surgery including transurethral resection of the prostate (turp)and prostatectomy. pro-cure causes regression of the enlarged prostate, improves urinary flow and improves the symptoms assocciated with bph. patients with an enlarged prostate are the appropriate candidates for therapy with pro-cure.

Singapor - Ingliż - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - meglumine amidotrizoate; sodium amidotrizoate - solution - 0.66 g/ml - meglumine amidotrizoate 0.66 g/ml; sodium amidotrizoate 0.1 g/ml

Filippini - Ingliż - FDA (Food And Drug Administration)

glovax biotech corp.; distributor: glovax biotech corp. - diphtheria, tetanus, pertussis hepatitis b recombinant and haemophilus influenza b type (hib) vaccine (see formulation on reverse side) - suspension for injection (im) - each 0.5 ml contains: diphteria toxoid 25 lf > 30 iu tetanus toxoid 5.5 lf > 60 iu b. pertussis (whole cell) 16 iou >

Filippini - Ingliż - FDA (Food And Drug Administration)

glovax biotech corp.; distributor: glovax biotech corp. - diphtheria, tetanus, pertussis, hepatitis b recombinant and haemophilus influenza b type (hib) vaccine - suspension for injection (im) - each 0.5ml contains: 25 lf> 30 iu 5.5 lf> 60 iu 16 iou ( 4 iu) diphtheria toxoid tetanus toxoid b. pertussis (whole

Filippini - Ingliż - FDA (Food And Drug Administration)

genpharm, inc.; distributor: genpharm, inc. - diphtheria-tetanus toxoids and pertussis ( dtp ) vaccines - suspension for injection (im) (monodose) - 30 iu (25 lf) / 40 iu (5 lf) / 4 iu per 0.5 ml